Daiichi Pharmaceutical Korea to Become Wholly Owned Subsidiary of Daiichi Pharmaceutical.Tokyo, Japan, Oct 10, 2006 - (JCN JCN Japan Corporate News JCN Journal of Cognitive Neuroscience JCN Journal of Cardiovascular Nursing JCN Journal of Christian Nursing JCN Job Control Number JCN Journal of Child Neurology JCN joint communications network (US DoD) ) - Daiichi Sankyo Co., Ltd. has announced that its subsidiary Daiichi Pharmaceutical Co., Ltd. has signed an agreement to acquire 100% of the shares of Seoul-based Daiichi Pharmaceutical Korea Co., Ltd. ('KDP'), a joint venture with Jeil Pharmaceutical Co., Ltd. The acquisition will take effect on October 13, when KDP KDP Kurdistan Democratic Party KDP Kappa Delta Pi (Education Honors Society) KDP Kurdish Democratic Party KDP Key Decision Point KDP Key Data Processor KDP Potassium Di-hydrogen Phosphate KDP Keyboard Data Processing becomes a wholly owned subsidiary Wholly Owned Subsidiary A subsidiary whose parent company owns 100% of its common stock. Notes: In other words, the parent company owns the company outright and there are no minority owners. of Daiichi Pharmaceutical. With this acquisition, the Daiichi Sankyo Group plans to actively expand its business operations Business operations are those activities involved in the running of a business for the purpose of producing value for the stakeholders. Compare business processes. The outcome of business operations is the harvesting of value from assets throughout Asia. Copyright [c] 2006 Japan Corporate News Network. All rights reserved. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion